ライフサイエンスコーパス: aluminum hydroxide

1 r placebo or RSVpreF (240 ug with or without aluminum hydroxide).

2 et v 1-specific antibodies in the absence of aluminum hydroxide.

3 injections in combination with the adjuvant aluminum hydroxide.

4 ke protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide.

5 g those who received RSVpreF vaccine without aluminum hydroxide.

6 nt and quality of allergoids in complex with aluminum hydroxide.

7 ss anchored Interleukin 12 (IL-12) linked to aluminum hydroxide.

8 icans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide.

9 were reduced in neonates immunized with OVA-aluminum hydroxide.

10 lymphocytes than unmodified nanoparticles or aluminum hydroxide.

11 ately Th2-biased responses with the adjuvant aluminum hydroxide.

12 ogenic effects of an authentic Th2 adjuvant, aluminum hydroxide.

13 nti-tumor immunity to the adjuvant action of aluminum hydroxide.

14 ccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide.

15 ent tolerance when the Ag is provided as OVA-aluminum hydroxide.

16 sion proteins in the absence and presence of aluminum hydroxide.

17 e and equal to purified proteins absorbed to aluminum hydroxide, a standard adjuvant.

18 e poorly immunogenic in mice vaccinated with aluminum hydroxide-absorbed formulations.

19 anched polyleucine (BL(10)), or with (5) CpG/aluminum hydroxide adjuvant (alum)-adjuvanted control an

20 han did a 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine; Engerix-

21 microgram of the III-alpha2r vaccine with an aluminum hydroxide adjuvant and bred.

22 ated from the formulation, which included an aluminum hydroxide adjuvant for analysis.

23 educing the particle size of the traditional aluminum hydroxide adjuvant into nanometers represents a

24 dose of vaccine (7 or 15 microg of HA) with aluminum hydroxide adjuvant or 2 doses (7 microg of HA e

25 G (IgG) responses in serum as effectively as aluminum hydroxide adjuvant.

26 d to generate allergoids and are adsorbed to aluminum hydroxide adjuvant.

27 d using standard i.p. OVA sensitization with aluminum hydroxide adjuvant.

28 3p-N vaccine is effective when combined with aluminum hydroxide adjuvant.

29 fective against S. aureus when combined with aluminum hydroxide adjuvant.

30 ed the antibody responses and efficacy of an aluminum hydroxide adjuvanted purified inactivated Zika

31 Mice were primed with aluminum hydroxide-adjuvanted UV-inactivated DENV prior

32 e challenged mice and mice immunized with an aluminum hydroxide-adjuvanted vaccine.

33 We tested a human-safe, aluminum hydroxide-adjuvanted whole-cell T. vaginalis va

34 studies demonstrated that immunization using aluminum hydroxide adjuvants induces Ag-specific Th2 res

35 ptor (PRR) agonists alone or formulated with aluminum hydroxide (AH) and benchmarked them against AS0

36 Aluminum hydroxide (AH) salts are the most widely used a

37 valent formulations, while still adsorbed on aluminum hydroxide (AH) suspension.

38 eres containing different vaccine adjuvants (aluminum hydroxide (Al(OH)(3)) or calcium phosphate).

39 Treatment with aqueous and aluminum hydroxide (Al[OH](3))-adsorbed purified honeybe

40 bovine serum albumin were better adsorbed to aluminum hydroxide (Alhydrogel).

41 n the canine rOspA vaccine was combined with aluminum hydroxide, all vaccinated hamsters developed ar

42 ion exchange accompanied by precipitation of aluminum hydroxide allows progress of the cation exchang

43 We evaluated the dose-sparing potential of aluminum hydroxide (AlOH) adjuvant.

44 ith Helicobacter antigen in combination with aluminum hydroxide (AlOH) was evaluated in a murine mode

45 glutinin (HA), with or without 600 microg of aluminum hydroxide (AlOH), or 3.75 microg of HA, with or

46 60, 120, or 240 ug RSVpreF (with or without aluminum hydroxide) alone or concomitantly with seasonal

47 hree clinically relevant adjuvants [3M-052 + aluminum hydroxide (Alum) (3M), a TLR7/8 agonist formula

48 Aluminum hydroxide (alum) adjuvant is the most widely av

49 sphoserine (pSer)-tagged immunogens bound to aluminum hydroxide (alum) adjuvant, promoting prolonged

50 oduced in Vero cell cultures and adsorbed to aluminum hydroxide (alum) adjuvant.

51 tetanus toxin (yP2P30Pv20019), formulated in aluminum hydroxide (alum) and block copolymer P1005.

52 In contrast to aluminum hydroxide (Alum) as adjuvant, formulation of rP

53 min(323-337) peptide, using either U1 RNA or aluminum hydroxide (alum) as the adjuvant.

54 ) versus either SE alone or the mineral salt aluminum hydroxide (alum) at the muscle injection site o

55 Aluminum hydroxide (alum) is the most commonly used vacc

56 Aluminum hydroxide (Alum) is the only adjuvant approved

57 ke (S) protein formulated with either ILA or aluminum hydroxide (alum) using a systems serology appro

58 S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most poten

59 or 5 ug of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally w

60 Rowett rats were injected with aluminum hydroxide (alum) with buffer, alum-GTF, or alum

61 d with phosphonates to allow adsorption onto aluminum hydroxide (alum), a formulation commonly used i

62 lux; dithiocarbamate, a metal ionophore; and aluminum hydroxide (alum), an immunological adjuvant.

63 responses both in quantity and quality than aluminum hydroxide (alum), which is currently the most w

64 from Escherichia coli or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1.

65 stimulates low Ab levels when combined with aluminum hydroxide (alum).

66 eek intervals with MOMP and CpG suspended in aluminum hydroxide (alum).

67 rgp120 with MF59 (n=48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) betwe

68 ken gamma-globulin (NP-CGG) and the adjuvant aluminum-hydroxide (alum) have been proposed to be matur

69 diated by anchoring these IFNs to coinjected aluminum-hydroxide (alum) particles, greatly improved bo

70 xpressed in Escherichia coli and adsorbed to aluminum hydroxide, an adjuvant approved for human use,

71 Finally, when adjuvanted with aluminum hydroxide and administered to BDD-naive calves

72 or 120 microg of recombinant OspA (rOspA) in aluminum hydroxide and challenged with B. burgdorferi se

73 h a killed bacterial vaccine adjuvanted with aluminum hydroxide and the involvement of gammadelta T c

74 xt of both traditional protein/adjuvant (OVA/aluminum hydroxide) and CD8(+)-specific heat shock prote

75 a human hepatitis B vaccine adjuvanted with aluminum hydroxide, and a human papillomavirus vaccine a

76 We show that i.m. priming of mice with an aluminum hydroxide- and BcfA-adjuvanted spike subunit va

77 mice with each of the proteins adsorbed onto aluminum hydroxide as adjuvant, we measured serum IgG re

78 kout mice with an i.p. injection of OVA with aluminum hydroxide as an adjuvant and treated the mice w

79 age with rLigA (rLigAcon and rLigAvar) with aluminum hydroxide as an adjuvant.

80 vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), el

81 with formalin-inactivated B. burgdorferi in aluminum hydroxide, but not recombinant OspA.

82 ne boosting effect of four common adjuvants: aluminum hydroxide, calcium phosphate, incomplete Freund

83 d that induction of tolerance to proteins in aluminum hydroxide can be achieved in Foxp3-deficient mi

84 ctivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide can cause enhanced respiratory diseas

85 ately, despite its favorable safety profile, aluminum hydroxide can only weakly or moderately potenti

86 of aluminum salts (i.e., up to ~1%, w/v, of aluminum hydroxide) can be converted into a dry powder b

87 The epsilon-Al(13) Keggin aluminum hydroxide clusters are essential models in esta

88 f a block copolymer water-in-oil emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotid

89 keyhole limpet hemocyanin adsorbed to Imject aluminum hydroxide-containing adjuvant or mixed with alp

90 e vaccinated with these proteins adsorbed to aluminum hydroxide developed strong antibody responses a

91 e antibody response, whereas the addition of aluminum hydroxide did not.

92 roscopy to directly observe the growth of an aluminum hydroxide film from an aqueous solution and cha

93 When dispersed in an aqueous solution, aluminum hydroxide forms particulates of 1-20mum.

94 Adsorption of the conjugates onto aluminum hydroxide further increased the antibody respon

95 uctures of six model proteins, adsorbed onto aluminum hydroxide gel (Alhydrogel) or in aqueous soluti

96 eund adjuvant but not when it is adsorbed to aluminum hydroxide gel (alum).

97 , San Diego, Ca) and the clinically approved Aluminum hydroxide gel (Alum, Invivogen, San Diego, Ca)

98 nensis with human rIL-12 (rhIL-12) and alum (aluminum hydroxide gel) as adjuvants.

99 major SEAgs coadministered with either alum (aluminum hydroxide gel) or recombinant murine interleuki

100 inflammation than recombinant PA adsorbed to aluminum hydroxide gel.

101 ctivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide have been critical to the COVID-19 pa

102 or with, but not after, H1/CAF01 or H1/CpG/ aluminum hydroxide immunization.

103 ence of Act1 expression in T cells after OVA/aluminum hydroxide immunization.

104 SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques.

105 he combined vaccine antigens formulated with aluminum hydroxide induced antibodies with opsonophagocy

106 F4 agonists were potent costimulators of OVA/aluminum hydroxide-induced CD4(+) Tconv proliferation, b

107 roup A streptococcal vaccine formulated with aluminum hydroxide into the deltoid muscle of alternatin

108 Aluminum hydroxide is an efficient binder; however, its

109 Aluminum hydroxide is used as a vaccine adjuvant in vari

110 protein antigens adsorbed on the traditional aluminum hydroxide microparticles of around 9.3mum.

111 developed a protein-free vaccine composed of aluminum hydroxide, monophosphoryl lipid A, and fungal m

112 nalizing porous activated carbon cloths with aluminum hydroxide nanoparticles (Al(OH)(3)-p-ACC).

113 Finally, the local inflammation induced by aluminum hydroxide nanoparticles in the injection sites

114 showed that protein antigens adsorbed on the aluminum hydroxide nanoparticles induced a stronger anti

115 In the present study, we synthesized aluminum hydroxide nanoparticles of 112nm.

116 The potent adjuvant activity of the aluminum hydroxide nanoparticles was likely related to t

117 , or parenterally immunized with urease plus aluminum hydroxide or a glycolipid adjuvant, challenged

118 g ovalbumin as a model antigen adsorbed onto aluminum hydroxide or aluminum phosphate, a commercially

119 unotherapy (ILIT) with MAT-Feld1 adsorbed to aluminum hydroxide or just aluminum hydroxide (placebo)

120 y either systemic administration of OVA with aluminum hydroxide or mucosal administration of OVA with

121 the season, Bet v 1 COPs (50 and 100 mug in aluminum hydroxide) or placebo (saline and aluminum hydr

122 240 mug of RSVpreF vaccine (with or without aluminum hydroxide) or placebo.

123 that adsorption onto hydrophilic surfaces of aluminum hydroxide particles did not alter the secondary

124 The high density of the aluminum hydroxide particles enabled pelleting the antig

125 laining its role as a precursor to amorphous aluminum hydroxide phases.

126 Feld1 adsorbed to aluminum hydroxide or just aluminum hydroxide (placebo) in a double-blind setting.

127 P adjuvanted with human-applicable alum-MPL (aluminum hydroxide plus 3-O-desacyl-4'-monophosphoryl li

128 oulant molecules along with any carried-over aluminum hydroxide precipitates evidenced by increasing

129 on pathway from aqueous aluminum monomers to aluminum hydroxide precipitates.

130 methods, including nepheline syenite, lime, aluminum hydroxide, precipitation, and hydrothermal proc

131 sponses, whereas incorporation of IL-12 with aluminum hydroxide produces a Th1 inducing adjuvant.

132 eptide linkers that promote tight binding to aluminum hydroxide (pSer:alum).

133 s (CFP), prepared in a variety of adjuvants (aluminum hydroxide, Quil-A, and dimethyldioctyldecyl amm

134 The i.p. injection of OVA/aluminum hydroxide restored development of the AHR enhan

135 ic Th17 cells transferred in vivo to OVA and aluminum hydroxide-sensitized mice also maintained IL-17

136 mouse, and adsorption of the conjugates onto aluminum hydroxide significantly increased the antibody

137 odentate inner-sphere surface complex on the aluminum hydroxide surface.

138 omen who received RSVpreF vaccine containing aluminum hydroxide than among those who received RSVpreF

139 We compared classical adjuvants such as aluminum hydroxide to new preclinical adjuvants and adju

140 immunization with tetanus toxoid adsorbed to aluminum hydroxide (TT/Alum).

141 igate the mechanism of phosphate sorption on aluminum hydroxides under different environmental condit

142 able with the historical recombinant PA plus aluminum hydroxide vaccine administered s.c.

143 ts are important because an rOspA vaccine in aluminum hydroxide was approved by the Food and Drug Adm

144 n aluminum hydroxide) or placebo (saline and aluminum hydroxide) were administered as 5 subcutaneous

145 fic compound 23 alone or combined with alum (aluminum hydroxide wet gel) showed adjuvant activity for

146 re Ag sensitized by i.p. injection of OVA in aluminum hydroxide, with or without 50 mug of Salp15, on

147 ) whether adsorption of conjugate vaccine to aluminum hydroxide would improve immunogenicity and (ii)